CClinicalTrials.gg
RecruitingNCT07245394SHIFT-IBDUpdated Aug 31, 2026

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

An observational study in Inflammatory Bowel Disease (IBD), Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by TIDHI Innovation Inc.. Recruiting at 14 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by TIDHI Innovation Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.

Patients will begin guselkumab based on their doctor's decision. If eligible, they may be invited to participate in the study, which involves monitoring symptoms, test results, and overall health over the course of one year.

Guselkumab will be given according to local medical guidelines. Doctors can adjust the treatment as needed, just like in routine care.

Researchers believe that switching to guselkumab may be as effective as other advanced treatments. For those who saw some improvement on ustekinumab but not enough, guselkumab may offer better symptom control-without worsening results on medical tests like endoscopy.

The goal is to explore better treatment options for people whose IBD has not been well controlled with current therapies.

02

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)
  • IBD-unclassified (IBD-U)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

IBD patients who had inadequate response to ustekinumab and switched therapy to guselkumab.

Inclusion criteria

  • Subjects of any gender aged ≥ 18.
  • Confirmed diagnosis of IBD (CD, UC, or IBDU) for at least 6 months prior to baseline visit. Subjects with IBDU will be grouped with subjects with UC. The CD proportion of patients will be capped at 75%.
  • Subjects have received ustekinumab for at least 14 weeks and who are currently on or recently discontinued ustekinumab therapy.
  • For subjects that have recently discontinued ustekinumab, the last dose of ustekinumab must have been within 12 weeks before Week 0, and no other advanced therapy (i.e., infliximab, adalimumab, golimumab, certolizumab pegol, vedolizumab, natalizumab, risankizumab, mirikizumab, tofacitinib, upadacitinib, ozanimod, etrasimod) was started since stopping ustekinumab.
  • Subjects with an inadequate response to ustekinumab who require a change in advanced therapy and are initiating guselkumab, as determined by the treating physician.
  • For subjects on off-label ustekinumab dosing (90 mg every 4 or 6 weeks (off-label dosing), enrollment will be capped at 60%.
  • Ability and willingness to give written informed consent and comply with the requirements of this study protocol.
  • Subjects who have evidence of ongoing endoscopic evidence of disease activity within 3 months prior to Week 0, defined as:

    • For Crohn's Disease: Colonoscopy showing SES-CD score (excluding the presence of narrowing component) of ≥6 (or ≥4 for participants with isolated ileal disease), OR presence of ulcers larger than 5 mm in any segment.
    • For Ulcerative Colitis: Colonoscopy showing Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score ≥4, OR presence of erosions or ulcers in any segment.

Exclusion criteria

Exclusion Criteria:

  • History of prior exposure to any anti-p19 inhibitor (risankizumab or mirikizumab).
  • Subjects with formal contraindication to guselkumab per the drug label.
  • Use of guselkumab for an off-label indication, dosing regimen, or route of administration. Subjects who did not receive guselkumab induction will be excluded.
  • Subjects with an ostomy or ileo-anal pouch.
  • Subjects with a history of bowel surgery within 6 months prior to Week 0.
  • Subjects displaying clinical signs of acute severe UC, fulminant colitis or toxic megacolon within 3 months prior to Week 0.
  • Subjects who are expected to require bowel surgery by their IBD physician within the year of enrollment.
  • Subjects on 1 or more concomitant biologics.
  • Subjects with a history of colonic dysplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Note: Patients with a history of indefinite for dysplasia would be eligible.
  • Subjects with formal contraindication or unwilling to undergo lower endoscopy.
  • The patient is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Early Switch Cohort (ESC)

    Patients with CD or UC who had inadequate response to on-label maintenance ustekinumab (90 mg every 8 weeks) that requires a change in advanced therapy, as determined by the treating physician. Inadequate response could be either loss of response, partial response, or persistent endoscopic activity.

    Biological: Guselkumab (Tremfya)

  • Exhausted Ustekinumab Cohort (EUC)

    Patients with CD or UC who had inadequate response to off-label maintenance ustekinumab (90 mg every 6 or 4 weeks) that requires a change in advanced therapy, as determined by the treating physician. Inadequate response could be either loss of response, partial response, or persistent endoscopic activity.

    Biological: Guselkumab (Tremfya)

Interventions

  • BiologicalGuselkumab (Tremfya)

    Switching to Guselkumab (Tremfya) in People With Active IBD Previously Treated With Ustekinumab.

05

What researchers measure

Primary outcomes

  1. Rate of participants achieving deep remission in IBD patients treated with guselkumab after switching from ustekinumab

    Deep remission is defined as both absence of symptomatic worsening and endoscopic remission. Outcomes will be reported as the proportion of participants achieving deep remission at Week 52.

    Time frame: Week 52

  2. Rate of participants achieving deep remission, stratified by cohorts

    Deep remission is defined as both absence of symptomatic worsening and endoscopic remission. Outcomes will be reported as the proportion of participants achieving deep remission at Week 52 and stratified by Early Switch Cohort (ESC) and Exhausted Ustekinumab Cohort (EUC).

    Time frame: Week 52

Secondary outcomes

  1. Rate of participants with absence of symptomatic worsening

    Absence of symptomatic worsening defined as the absence of: 1. For Crohn's disease: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily abdominal pain score (APS) compared to Baseline. 2. For ulcerative colitis: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily rectal bleeding score (RBS) compared to Baseline.

    Time frame: Week 52

  2. Rate of participants achieving endoscopic remission

    Endoscopic remission is defined as follows: 1. For Crohn's disease: A Simple Endoscopic Score for Crohn's Disease (SDS-CD) of 4 or less, or a score of 2 or less in the ileal segment (excluding the narrowing component) in cases of disease limited to the ileum, with an ulceration subscore of 0. 2. For ulcerative colitis: A Ulcerative Colitis Endoscopic Index of Severity (UCEIS) of 1 or less, with a bleeding subscore of 0 and an erosions/ulcers subscore of 0.

    Time frame: Week 52

  3. Rate of participants achieving endoscopic response

    Endoscopic response is defined as follows: 1. For Crohn's disease: A reduction of 50 percent or more in the Simple Endoscopic Score for Crohn's Disease (SDS-CD) compared to Baseline (excluding the narrowing component). 2. For ulcerative colitis: A reduction of 2 points or more in the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) compared to baseline.

    Time frame: Week 52

  4. Rate of participants with absence of symptomatic worsening

    Absence of symptomatic worsening defined as the absence of: 1. For Crohn's disease: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily abdominal pain score (APS) compared to the baseline value. 2. For ulcerative colitis: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily rectal bleeding score (RBS) compared to Baseline.

    Time frame: Any study visit (Week 4, Week 12, Week 32, Week 52)

  5. Rate of participants achieving symptomatic remission among those not in remission at baseline

    Time frame: Week 12 and Week 52

  6. Rate of participants achieving steroid-free remission among corticosteroid users at baseline

    Steroid-free remission defined as no corticosteroid use and meeting symptomatic remission criteria

    Time frame: Week 52

  7. Rate of participants discontinuing guselkumab therapy

    Time frame: Any study visit (Week 4, Week 12, Week 32, Week 52)

Other outcomes

  1. Rate of participants achieving early symptomatic response among those not in symptomatic remission at baseline

    Early symptomatic response at week 4 among patients who were not in symptomatic remission at baseline is defined as follows: 1. For Crohn's disease: A decrease of 30 percent or more in the average daily stool frequency score (SFS) and/or a decrease of 30 percent or more in the average daily abdominal pain score (APS), with both scores not worse than Baseline. 2. For ulcerative colitis: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily rectal bleeding score (RBS) compared to Baseline.

    Time frame: Week 4

  2. Rate of participants achieving biochemical remission

    Biochemical remission at among patients with available fecal calprotectin (FCAL) and C-reactive protein (CRP). Biochemical remission is defined as FCAL ≤250 ug/g AND a CRP ≤5 mg/L among patients with available either an elevated FCAL or CRP at baseline.

    Time frame: Week 52

  3. Rate of participants achieving biochemical remission

    Biochemical remission at among patients with available fecal calprotectin (FCAL) and C-reactive protein (CRP). Biochemical remission is defined as FCAL ≤250 ug/g AND a CRP ≤5 mg/L among patients with available either an elevated FCAL or CRP at baseline.

    Time frame: Week 12

  4. Change from baseline in quality of life

    Quality of Life (QoL) outcomes will be reported as the change from baseline, using the following assessments: EuroQoL 5-Dimension 5-Level questionnaire (EQ-5D-5L): This tool evaluates five dimensions of health, each rated on a scale from 1 to 5. Higher scores indicate worse health status. Short Form Health Survey (SF-36): This questionnaire measures eight health domains, with each domain scored from 0 to 100. Higher scores reflect better health status.

    Time frame: Week 52

  5. Change from baseline in work productivity

    Work Productivity outcomes will be reported as the change from baseline, assessed using the Work Productivity and Activity Impairment questionnaires specific to Crohn's disease (WPAI-CD) and ulcerative colitis (WPAI-UC). Scores range from 0 to 100 percent, with higher percentages indicating greater impairment in work and daily activities.

    Time frame: Week 52

  6. Change from baseline in mental health (anxiety)

    Mental Health (anxiety) outcomes will be reported as the change from baseline, assessed using the Generalized Anxiety Disorder 7-item Scale (GAD-7): Scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.

    Time frame: Week 52

  7. Change from baseline in mental health (depression)

    Mental Health (depression) outcomes will be reported as the change from baseline, assessed using the Patient Health Questionnaire-9 (PHQ-9): Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Week 52

  8. Change from baseline in fatigue

    Fatigue outcomes will be reported as the change from baseline, assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F). Scores range from 0 to 52, with higher scores indicating less fatigue and better functioning.

    Time frame: Week 52

06

Study locations

12 of 14 sites recruiting
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
    Recruiting
  • MA MacMillan
    Fredericton, New Brunswick E3B 1J5, Canada
    • Mark MacMillan, MD, FRCPC, CAGF · Contact · mamacmil@me.com · (506)454-6682
    • Mark MacMilan, MD, FRCPC, CAGF · Principal investigator
    Recruiting
  • Hamilton Health Sciences Corporation
    Hamilton, Ontaio L8L 2X2, Canada
    • Jaimin Patel · Contact · patej102@mcmaster.ca · 905-521-2100
    • Neeraj Narula, MD · Principal investigator
    Not yet recruiting
  • Barrie GI Associates
    Barrie, Ontario L4M 7G1, Canada
    Recruiting
  • Brampton Gastroenterology Research Group Inc
    Brampton, Ontario L6S 0C1, Canada
    Recruiting
  • GNRR Digestive Clinics and Research Center Inc.
    Brampton, Ontario L6S 0E2, Canada
    Recruiting
  • LDDI Clinical Trials Inc. dba London Digestive Disease Institute
    London, Ontario N6K 1M6, Canada
    • Beth Beauchamp, RN, BScN · Contact · bbeauchamp@lddi.ca · (519) 204-6333
    • Vipul Jairath, MD · Principal investigator
    Recruiting
  • West Gta Research Inc.
    Mississauga, Ontario L5M 2S4, Canada
    Recruiting
  • Abp Research Services Corporation
    Oakville, Ontario L6L 5L7, Canada
    Recruiting
  • Taunton Surgical Center
    Oshawa, Ontario L1J 0C7, Canada
    • Alana Carter, BSN, MN · Contact · alanacarter01@gmail.com · 905-723-8551
    • Daniel Green, MD · Principal investigator
    Recruiting
  • Toronto Immune and Digestive Health Institute
    Toronto, Ontario M6A3B4, Canada
    • Kaitlyn Mitchell, RN, BScN, MSc · Contact · kmitchell@tidhi.ca · 647-812-2113
    • Janet Saad · Contact · mschwartz@tidhi.ca · 647-812-2113
    • Petros Zesos, MD · Principal investigator
    Recruiting
  • CIUSSS l'Est-de-l'Île-de-Montréal
    Montreal, Quebec H1T 2M4, Canada
    Not yet recruiting
  • The Research Institute of the McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
    Recruiting
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec, Canada
    Recruiting
07

Registry details

Key details

Study ID
NCT07245394
Lead sponsor
TIDHI Innovation Inc.
Collaborators
Janssen Inc.
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Jan 29, 2026
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Ajani Jeyakumar, HBSc BScN RN
Contact
ajeyakumar@tidhi.ca
647-812-2113
Katy Staikin, MSc
Contact
kstaikin@tidhi.ca
647-812-2113
Laura E. Targownik, MD, MSHS, FRCPC
principal investigator · TIDHI Innovation Inc.
Mark Silverberg, MD, PhD, FRCPC
principal investigator · TIDHI Innovation Inc.
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion